secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0000950103-22-019454
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen Q3 net loss $7.6M; cash $153.8M; retired $144M convertible notes
-------------------------------------------------------------------------

- Net loss from continuing ops $7.6M ($0.04/sh) vs $26.3M loss; total revenues up $13.4M (>200%) YoY.
- Cash, equivalents, short-term investments and restricted cash totaled $153.8M as of Sep 30, 2022.
- Retired $144M of $200M convertible notes due July 2023 at a discount; realized $5.4M savings.
- Clinical: Phase 1 enrollment complete for PRGN-2012 in RRP; virtual R&D event Jan 2023; ASH presentations.
- Phase 1b expansion for PRGN-3006 at Mayo Clinic; first patient dosed; FDA clearance for repeat dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010322019454/0000950103-22-019454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010322019454/dp184115_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-22-019454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer